Copyright Reports & Markets. All rights reserved.

Global and Japan Acquired Immunodeficiency Syndrome Market Size, Status and Forecast 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Market Analysis by Type
      • 1.2.1 Global Acquired Immunodeficiency Syndrome Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
      • 1.2.2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      • 1.2.3 Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • 1.3 Market by Application
      • 1.3.1 Global Acquired Immunodeficiency Syndrome Market Share by Application: 2016 VS 2021 VS 2027
      • 1.3.2 Hospital Pharmacy
      • 1.3.3 Retail Pharmacy
      • 1.3.4 Others
    • 1.4 Study Objectives
    • 1.5 Years Considered

    2 Global Growth Trends

    • 2.1 Global Acquired Immunodeficiency Syndrome Market Perspective (2016-2027)
    • 2.2 Acquired Immunodeficiency Syndrome Growth Trends by Regions
      • 2.2.1 Acquired Immunodeficiency Syndrome Market Size by Regions: 2016 VS 2021 VS 2027
      • 2.2.2 Acquired Immunodeficiency Syndrome Historic Market Share by Regions (2016-2021)
      • 2.2.3 Acquired Immunodeficiency Syndrome Forecasted Market Size by Regions (2022-2027)
    • 2.3 Acquired Immunodeficiency Syndrome Industry Dynamic
      • 2.3.1 Acquired Immunodeficiency Syndrome Market Trends
      • 2.3.2 Acquired Immunodeficiency Syndrome Market Drivers
      • 2.3.3 Acquired Immunodeficiency Syndrome Market Challenges
      • 2.3.4 Acquired Immunodeficiency Syndrome Market Restraints

    3 Competition Landscape by Key Players

    • 3.1 Global Top Acquired Immunodeficiency Syndrome Players by Revenue
      • 3.1.1 Global Top Acquired Immunodeficiency Syndrome Players by Revenue (2016-2021)
      • 3.1.2 Global Acquired Immunodeficiency Syndrome Revenue Market Share by Players (2016-2021)
    • 3.2 Global Acquired Immunodeficiency Syndrome Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    • 3.3 Players Covered: Ranking by Acquired Immunodeficiency Syndrome Revenue
    • 3.4 Global Acquired Immunodeficiency Syndrome Market Concentration Ratio
      • 3.4.1 Global Acquired Immunodeficiency Syndrome Market Concentration Ratio (CR5 and HHI)
      • 3.4.2 Global Top 10 and Top 5 Companies by Acquired Immunodeficiency Syndrome Revenue in 2020
    • 3.5 Acquired Immunodeficiency Syndrome Key Players Head office and Area Served
    • 3.6 Key Players Acquired Immunodeficiency Syndrome Product Solution and Service
    • 3.7 Date of Enter into Acquired Immunodeficiency Syndrome Market
    • 3.8 Mergers & Acquisitions, Expansion Plans

    4 Acquired Immunodeficiency Syndrome Breakdown Data by Type

    • 4.1 Global Acquired Immunodeficiency Syndrome Historic Market Size by Type (2016-2021)
    • 4.2 Global Acquired Immunodeficiency Syndrome Forecasted Market Size by Type (2022-2027)

    5 Acquired Immunodeficiency Syndrome Breakdown Data by Application

    • 5.1 Global Acquired Immunodeficiency Syndrome Historic Market Size by Application (2016-2021)
    • 5.2 Global Acquired Immunodeficiency Syndrome Forecasted Market Size by Application (2022-2027)

    6 North America

    • 6.1 North America Acquired Immunodeficiency Syndrome Market Size (2016-2027)
    • 6.2 North America Acquired Immunodeficiency Syndrome Market Size by Type
      • 6.2.1 North America Acquired Immunodeficiency Syndrome Market Size by Type (2016-2021)
      • 6.2.2 North America Acquired Immunodeficiency Syndrome Market Size by Type (2022-2027)
      • 6.2.3 North America Acquired Immunodeficiency Syndrome Market Size by Type (2016-2027)
    • 6.3 North America Acquired Immunodeficiency Syndrome Market Size by Application
      • 6.3.1 North America Acquired Immunodeficiency Syndrome Market Size by Application (2016-2021)
      • 6.3.2 North America Acquired Immunodeficiency Syndrome Market Size by Application (2022-2027)
      • 6.3.3 North America Acquired Immunodeficiency Syndrome Market Size by Application (2016-2027)
    • 6.4 North America Acquired Immunodeficiency Syndrome Market Size by Country
      • 6.4.1 North America Acquired Immunodeficiency Syndrome Market Size by Country (2016-2021)
      • 6.4.2 North America Acquired Immunodeficiency Syndrome Market Size by Country (2022-2027)
      • 6.4.3 United States
      • 6.4.4 Canada

    7 Europe

    • 7.1 Europe Acquired Immunodeficiency Syndrome Market Size (2016-2027)
    • 7.2 Europe Acquired Immunodeficiency Syndrome Market Size by Type
      • 7.2.1 Europe Acquired Immunodeficiency Syndrome Market Size by Type (2016-2021)
      • 7.2.2 Europe Acquired Immunodeficiency Syndrome Market Size by Type (2022-2027)
      • 7.2.3 Europe Acquired Immunodeficiency Syndrome Market Size by Type (2016-2027)
    • 7.3 Europe Acquired Immunodeficiency Syndrome Market Size by Application
      • 7.3.1 Europe Acquired Immunodeficiency Syndrome Market Size by Application (2016-2021)
      • 7.3.2 Europe Acquired Immunodeficiency Syndrome Market Size by Application (2022-2027)
      • 7.3.3 Europe Acquired Immunodeficiency Syndrome Market Size by Application (2016-2027)
    • 7.4 Europe Acquired Immunodeficiency Syndrome Market Size by Country
      • 7.4.1 Europe Acquired Immunodeficiency Syndrome Market Size by Country (2016-2021)
      • 7.4.2 Europe Acquired Immunodeficiency Syndrome Market Size by Country (2022-2027)
      • 7.4.3 Germany
      • 7.4.4 France
      • 7.4.5 U.K.
      • 7.4.6 Italy
      • 7.4.7 Russia
      • 7.4.8 Nordic

    8 Asia-Pacific

    • 8.1 Asia-Pacific Acquired Immunodeficiency Syndrome Market Size (2016-2027)
    • 8.2 Asia-Pacific Acquired Immunodeficiency Syndrome Market Size by Type
      • 8.2.1 Asia-Pacific Acquired Immunodeficiency Syndrome Market Size by Type (2016-2021)
      • 8.2.2 Asia-Pacific Acquired Immunodeficiency Syndrome Market Size by Type (2022-2027)
      • 8.2.3 Asia-Pacific Acquired Immunodeficiency Syndrome Market Size by Type (2016-2027)
    • 8.3 Asia-Pacific Acquired Immunodeficiency Syndrome Market Size by Application
      • 8.3.1 Asia-Pacific Acquired Immunodeficiency Syndrome Market Size by Application (2016-2021)
      • 8.3.2 Asia-Pacific Acquired Immunodeficiency Syndrome Market Size by Application (2022-2027)
      • 8.3.3 Asia-Pacific Acquired Immunodeficiency Syndrome Market Size by Application (2016-2027)
    • 8.4 Asia-Pacific Acquired Immunodeficiency Syndrome Market Size by Region
      • 8.4.1 Asia-Pacific Acquired Immunodeficiency Syndrome Market Size by Region (2016-2021)
      • 8.4.2 Asia-Pacific Acquired Immunodeficiency Syndrome Market Size by Region (2022-2027)
      • 8.4.3 China
      • 8.4.4 Japan
      • 8.4.5 South Korea
      • 8.4.6 Southeast Asia
      • 8.4.7 India
      • 8.4.8 Australia

    9 Latin America

    • 9.1 Latin America Acquired Immunodeficiency Syndrome Market Size (2016-2027)
    • 9.2 Latin America Acquired Immunodeficiency Syndrome Market Size by Type
      • 9.2.1 Latin America Acquired Immunodeficiency Syndrome Market Size by Type (2016-2021)
      • 9.2.2 Latin America Acquired Immunodeficiency Syndrome Market Size by Type (2022-2027)
      • 9.2.3 Latin America Acquired Immunodeficiency Syndrome Market Size by Type (2016-2027)
    • 9.3 Latin America Acquired Immunodeficiency Syndrome Market Size by Application
      • 9.3.1 Latin America Acquired Immunodeficiency Syndrome Market Size by Application (2016-2021)
      • 9.3.2 Latin America Acquired Immunodeficiency Syndrome Market Size by Application (2022-2027)
      • 9.3.3 Latin America Acquired Immunodeficiency Syndrome Market Size by Application (2016-2027)
    • 9.4 Latin America Acquired Immunodeficiency Syndrome Market Size by Country
      • 9.4.1 Latin America Acquired Immunodeficiency Syndrome Market Size by Country (2016-2021)
      • 9.4.2 Latin America Acquired Immunodeficiency Syndrome Market Size by Country (2022-2027)
      • 9.4.3 Mexico
      • 9.4.4 Brazil

    10 Middle East & Africa

    • 10.1 Middle East & Africa Acquired Immunodeficiency Syndrome Market Size (2016-2027)
    • 10.2 Middle East & Africa Acquired Immunodeficiency Syndrome Market Size by Type
      • 10.2.1 Middle East & Africa Acquired Immunodeficiency Syndrome Market Size by Type (2016-2021)
      • 10.2.2 Middle East & Africa Acquired Immunodeficiency Syndrome Market Size by Type (2022-2027)
      • 10.2.3 Middle East & Africa Acquired Immunodeficiency Syndrome Market Size by Type (2016-2027)
    • 10.3 Middle East & Africa Acquired Immunodeficiency Syndrome Market Size by Application
      • 10.3.1 Middle East & Africa Acquired Immunodeficiency Syndrome Market Size by Application (2016-2021)
      • 10.3.2 Middle East & Africa Acquired Immunodeficiency Syndrome Market Size by Application (2022-2027)
      • 10.3.3 Middle East & Africa Acquired Immunodeficiency Syndrome Market Size by Application (2016-2027)
    • 10.4 Middle East & Africa Acquired Immunodeficiency Syndrome Market Size by Country
      • 10.4.1 Middle East & Africa Acquired Immunodeficiency Syndrome Market Size by Country (2016-2021)
      • 10.4.2 Middle East & Africa Acquired Immunodeficiency Syndrome Market Size by Country (2022-2027)
      • 10.4.3 Turkey
      • 10.4.4 Saudi Arabia
      • 10.4.5 UAE

    11 Key Players Profiles

    • 11.1 Takeda
      • 11.1.1 Takeda Company Details
      • 11.1.2 Takeda Business Overview
      • 11.1.3 Takeda Acquired Immunodeficiency Syndrome Introduction
      • 11.1.4 Takeda Revenue in Acquired Immunodeficiency Syndrome Business (2016-2021)
      • 11.1.5 Takeda Recent Development
    • 11.2 AstraZeneca Eli Lilly and Company
      • 11.2.1 AstraZeneca Eli Lilly and Company Company Details
      • 11.2.2 AstraZeneca Eli Lilly and Company Business Overview
      • 11.2.3 AstraZeneca Eli Lilly and Company Acquired Immunodeficiency Syndrome Introduction
      • 11.2.4 AstraZeneca Eli Lilly and Company Revenue in Acquired Immunodeficiency Syndrome Business (2016-2021)
      • 11.2.5 AstraZeneca Eli Lilly and Company Recent Development
    • 11.3 Merck KGaA
      • 11.3.1 Merck KGaA Company Details
      • 11.3.2 Merck KGaA Business Overview
      • 11.3.3 Merck KGaA Acquired Immunodeficiency Syndrome Introduction
      • 11.3.4 Merck KGaA Revenue in Acquired Immunodeficiency Syndrome Business (2016-2021)
      • 11.3.5 Merck KGaA Recent Development
    • 11.4 Sanofi
      • 11.4.1 Sanofi Company Details
      • 11.4.2 Sanofi Business Overview
      • 11.4.3 Sanofi Acquired Immunodeficiency Syndrome Introduction
      • 11.4.4 Sanofi Revenue in Acquired Immunodeficiency Syndrome Business (2016-2021)
      • 11.4.5 Sanofi Recent Development
    • 11.5 Pfizer
      • 11.5.1 Pfizer Company Details
      • 11.5.2 Pfizer Business Overview
      • 11.5.3 Pfizer Acquired Immunodeficiency Syndrome Introduction
      • 11.5.4 Pfizer Revenue in Acquired Immunodeficiency Syndrome Business (2016-2021)
      • 11.5.5 Pfizer Recent Development
    • 11.6 Amgen
      • 11.6.1 Amgen Company Details
      • 11.6.2 Amgen Business Overview
      • 11.6.3 Amgen Acquired Immunodeficiency Syndrome Introduction
      • 11.6.4 Amgen Revenue in Acquired Immunodeficiency Syndrome Business (2016-2021)
      • 11.6.5 Amgen Recent Development
    • 11.7 Biogen
      • 11.7.1 Biogen Company Details
      • 11.7.2 Biogen Business Overview
      • 11.7.3 Biogen Acquired Immunodeficiency Syndrome Introduction
      • 11.7.4 Biogen Revenue in Acquired Immunodeficiency Syndrome Business (2016-2021)
      • 11.7.5 Biogen Recent Development
    • 11.8 Novartis
      • 11.8.1 Novartis Company Details
      • 11.8.2 Novartis Business Overview
      • 11.8.3 Novartis Acquired Immunodeficiency Syndrome Introduction
      • 11.8.4 Novartis Revenue in Acquired Immunodeficiency Syndrome Business (2016-2021)
      • 11.8.5 Novartis Recent Development
    • 11.9 Actelion
      • 11.9.1 Actelion Company Details
      • 11.9.2 Actelion Business Overview
      • 11.9.3 Actelion Acquired Immunodeficiency Syndrome Introduction
      • 11.9.4 Actelion Revenue in Acquired Immunodeficiency Syndrome Business (2016-2021)
      • 11.9.5 Actelion Recent Development
    • 11.10 Daiichi Sankyo Company
      • 11.10.1 Daiichi Sankyo Company Company Details
      • 11.10.2 Daiichi Sankyo Company Business Overview
      • 11.10.3 Daiichi Sankyo Company Acquired Immunodeficiency Syndrome Introduction
      • 11.10.4 Daiichi Sankyo Company Revenue in Acquired Immunodeficiency Syndrome Business (2016-2021)
      • 11.10.5 Daiichi Sankyo Company Recent Development

    12 Analyst's Viewpoints/Conclusions

      13 Appendix

      • 13.1 Research Methodology
        • 13.1.1 Methodology/Research Approach
        • 13.1.2 Data Source
      • 13.2 Disclaimer

      Acquired immunodeficiency syndrome (AIDS) is one of the most widespread, catastrophic, and incurable diseases among humans in the world. According to a report published by the World Health Organization (WHO) in 2013, deaths caused by HIV ranked sixth in the total number of deaths in the world. Human immunodeficiency virus (HIV) presents itself as a complex mixture of symptoms, all related to severe immune compromise, while AIDS is an advanced stage of HIV infection.
      Market Snapshot
      A recently published report by QY Research, titled “Global Acquired Immunodeficiency Syndrome Market Size, Status and Forecast 2021-2027” gives an overview of the overall Acquired Immunodeficiency Syndrome market. This section sheds light on key impact-rendering drivers and constraints that are impacting the growth. It permits users to understand the different shortcomings and how they may hamper the development afterward. This segment is considered to be one of the most crucial segments of the report as it helps readers comprehend the impact of various macro and microeconomic factors on development. The role of various sectors, including small-scale and large-scale, in the expansion has also been discussed in the report. Additionally, the industry experts have put forth the current trends and prospects, which are likely to aid the growth in the upcoming years.
      The global Acquired Immunodeficiency Syndrome market size is projected to reach US$ million by 2027, from US$ million in 2020, at a CAGR of % during 2021-2027.
      Impact of Covid-19 Outbreak
      This section of the report has explored the overall status of the Covid scenario and has offered valuable insights into the changes in supply chain disruption, fluctuations in demand, etc. The analysts have also focused on the key measures that the companies are opting to withstand the harsh scenario.
      Segmental Analysis
      The report has been segmented into product and application segments. The researchers have documented all the products present today in the Acquired Immunodeficiency Syndrome market. They have also shed light on the new product innovations and launches by the key players. In the segmental analysis, the analysts have provided revenue forecast figures based on type and application for the period 2016-2027. They have also discussed about the growth rate and potential of each segment for the period 2016-2027.
      Acquired Immunodeficiency Syndrome Breakdown Data by Type
      Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
      Acquired Immunodeficiency Syndrome Breakdown Data by Application
      Hospital Pharmacy
      Retail Pharmacy
      Others
      Regional Analysis
      The significant regions that are studied in the research report encompass North America, Europe, Asia Pacific, Central and South America, and the Middle East and Africa. In this section of the report, the specialists have explored various areas that are contributing to the development and can present lucrative growth prospects for the manufacturers in the forthcoming years. The report also provides region-wise and country-wise sales and revenue forecast data for the period 2021-2027.
      Competitive Landscape
      This segment focuses on the key players operating in the industry. It underlines all the current and future activities by the prominent manufacturers. By understanding various initiatives being taken up by different players, readers will gain the ability to settle on correct business choices. The authors of the report have provided accurate revenue figures of the companies for the period 2016-2021. The clients are sure to gain the upper hand once they get hold of this report. Key players studied in the research report include:
      Takeda
      AstraZeneca Eli Lilly and Company
      Merck KGaA
      Sanofi
      Pfizer
      Amgen
      Biogen
      Novartis
      Actelion
      Daiichi Sankyo Company
      Buy now